Clinical Study ResultsThe combination treatment in Cohort B of the TACTI-003 study performed well even in patients with a worse prognosis, with over 50% of patients remaining on treatment at six months.
Market ReactionShares are up approximately 15% following the positive news of the efti and Keytruda combination achieving compelling overall response rates in head and neck cancer treatment.
Product PerformanceThe company's lead product candidate, eftilagimod alpha (efti), showed a 35.5% overall response rate (ORR) in advanced cancer treatment, which is very encouraging.